Den anden undersøgelse omfattede i alt 119 patienter, som var i den accelererede fase af sygdommen, hvoraf fire femtedele ikke længere responderede på imatinib.
The second study included a total of 119 patients whose disease was in the ‘ accelerated phase’, four fifths of whom had stopped responding to imatinib.